Glioblastoma in adults

Critical Reviews in Oncology/Hematology

Volumn 67, Issue 2, 2008, Pages 139-152

  Brandes, Alba A ^a   Tosoni, Alicia ^a   Franceschi, Enrico ^a   Reni, Michele ^b   Gatta, Gemma ^c   Vecht, Charles ^d  

^a BELLARIA HOSPITAL   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Neurology Medical Center   (Netherlands)

Author keywords

Chemotherapy; Glioblastoma; Radiotherapy; Review

Indexed keywords

1 (2 CHLOROETHYL) 3 (2,6 DIOXO 3 PIPERIDYL) 1 NITROSOUREA; BEVACIZUMAB; BLEOMYCIN; CARMUSTINE; CEDIRANIB; CISPLATIN; CYTARABINE; DACARBAZINE; EFAPROXIRAL; ERLOTINIB; GADOLINIUM; GADOLINIUM TEXAPHYRIN; GEFITINIB; HYDROXYUREA; IRINOTECAN; ISOTRETINOIN; LOMUSTINE; MARIMASTAT; MISONIDAZOLE; MITOLACTOL; NIMUSTINE; NITROSOUREA; PROCARBAZINE; SEMUSTINE; STREPTOZOCIN; TEMOZOLOMIDE; TEMSIROLIMUS; TENIPOSIDE; VINCRISTINE;

ADJUVANT THERAPY; ADULT; BLINDNESS; BLOOD TOXICITY; BRACHYTHERAPY; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER INFILTRATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; HUMAN; INTERMETHOD COMPARISON; LEUKOENCEPHALOPATHY; MONOTHERAPY; NEUTRON CAPTURE THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERIPHERAL NEUROPATHY; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION NECROSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; REVIEW; SCORING SYSTEM; SOMNOLENCE; STEREOTACTIC BIOPSY; STEREOTACTIC RADIOSURGERY; SURGICAL TECHNIQUE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; NEOPLASM STAGING;

EID: 45949107833     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.02.005     Document Type: Review

References (98)

1. Organization WWH, International Statistical Classification of Diseases and Related Health Problems, 10th revision. Geneva, 1992.
2. SEER, SEER*Stat Release 6.3.5. In, 2007.
3. ENCR, European Network of Cancer Registries. Eurocim version 4.0. European incidence database V2.2 (1999). Lyon. 2001.
4. Parkin D.M., Whelan S.L., and Ferlay J. Cancer incidence in five continents (2002), IARC, Lyon
5. Lonn S., Klaeboe L., Hall P., et al. Incidence trends of adult primary intracerebral tumors in four Nordic countries. Int J Cancer 108 (2004) 450-455
6. Capocaccia R., Gatta G., Roazzi P., et al. The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. Ann Oncol 14 Suppl 5 (2003) v14-v27
7. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 (2002) 1011-1018
8. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
9. Wrensch M., Minn Y., Chew T., et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-oncology 4 (2002) 278-299
10. Hardell L., Carlberg M., Soderqvist F., et al. Long-term use of cellular phones and brain tumours: increased risk associated with use for > or = 10 years. Occup Environ Med 64 (2007) 626-632
11. Wrensch M., Lee M., Miike R., et al. Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am J Epidemiol 145 (1997) 581-593
12. Grossman S.A., Osman M., Hruban R., and Piantadosi S. Central nervous system cancers in first-degree relatives and spouses. Cancer Invest 17 (1999) 299-308
13. Malmer B., Iselius L., Holmberg E., et al. Genetic epidemiology of glioma. Br J Cancer 84 (2001) 429-434
14. de Andrade M., Barnholtz J.S., Amos C.I., et al. Segregation analysis of cancer in families of glioma patients. Genet Epidemiol 20 (2001) 258-270
15. Malmer B., Henriksson R., and Gronberg H. Familial brain tumours-genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients. Int J Cancer 106 (2003) 260-263
16. Kleihues P., Louis D.N., Scheithauer B.W., et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61 (2002) 215-225 [discussion 226-219]
17. Aldape K., Simmons M.L., Davis R.L., et al. Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay Area Adult Glioma Study. Cancer 88 (2000) 2342-2349
18. Reifenberger G., Kros J.M., Burger P.C., et al. Pathology and genetics of tumors of the central nervous system (2000), IARC press, Lyon
19. Ohgaki H., Dessen P., Jourde B., et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 64 (2004) 6892-6899
20. In: De Vita VT H.S., and Rosenberg S.A. (Eds). Cancer principles and practice of oncology (2001), Lippincott Williams & Wilkins
21. Lee P.L., and Gonzalez R.G. Magnetic resonance spectroscopy of brain tumors. Curr Opin Oncol 12 (2000) 199-204
22. Cao Y., Sundgren P.C., Tsien C.I., et al. Physiologic and metabolic magnetic resonance imaging in gliomas. J Clin Oncol 24 (2006) 1228-1235
23. Kumar A.J., Leeds N.E., Fuller G.N., et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217 (2000) 377-384
24. In: Sobin L.H., and Wittekind C. (Eds). UICC (International Union Against Cancer). TNM classification of malignant tumours (1997), Wiley-Liss, New York, Chichester, weinheim, Brisbane, Singapore, Toronto
25. Curran Jr. W.J., Scott C.B., Horton J., et al. Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 85 (1993) 704-710
26. Mirimanoff R.O., Gorlia T., Mason W., et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24 (2006) 2563-2569
27. Chang C.H., Horton J., Schoenfeld D., et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 52 (1983) 997-1007
28. Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group. J Neurosurg 1981;55:27-31.
29. Deutsch M., Green S.B., Strike T.A., et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 16 (1989) 1389-1396
30. Simpson J.R., Horton J., Scott C., et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26 (1993) 239-244
31. Wood J.R., Green S.B., and Shapiro W.R. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 6 (1988) 338-343
32. Hess K.R., Wong E.T., Jaeckle K.A., et al. Response and progression in recurrent malignant glioma. Neuro-oncology 1 (1999) 282-288
33. Long D.M., Gordon T., Bowman H., et al. Outcome and cost of craniotomy performed to treat tumors in regional academic referral centers. Neurosurgery 52 (2003) 1056-1063 [discussion 1063-1055]
34. Kristiansen K., Hagen S., Kollevold T., et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 47 (1981) 649-652
35. Walker M.D., Alexander Jr. E., Hunt W.E., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49 (1978) 333-343
36. Brada M. Current approaches to radiation therapy for malignant gliomas. Front Radiat Ther Oncol 33 (1999) 139-149
37. Brandes A.A., Rigon A., and Monfardini S. Radiotherapy of the brain in elderly patients. Contra Eur J Cancer 36 (2000) 447-451 [discussion 451-442]
38. Keime-Guibert F., Chinot O., Taillandier L., et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 356 (2007) 1527-1535
39. Roa W., Brasher P.M., Bauman G., et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22 (2004) 1583-1588
40. Laperriere N.J., Leung P.M., McKenzie S., et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 41 (1998) 1005-1011
41. Payne D.G., Simpson W.J., Keen C., and Platts M.E. Malignant astrocytoma: hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial. Cancer 50 (1982) 2301-2306
42. Prados M.D., Wara W.M., Sneed P.K., et al. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 49 (2001) 71-77
43. Tsao M.N., Lloyd N.S., Wong R.K., et al. Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev 31 (2005) 256-273
44. Kleinberg L., Grossman S.A., Piantadosi S., et al. Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme. J Clin Oncol 17 (1999) 2593-2603
45. Shaw E., Scott C., Suh J., et al. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J Clin Oncol 21 (2003) 2364-2371
46. Ford J.M., Seiferheld W., Alger J.R., et al. Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 69 (2007) 831-838
47. Fine H.A., Dear K.B., Loeffler J.S., et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71 (1993) 2585-2597
48. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005) 997-1003
49. Weller M., Muller B., Koch R., et al. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 21 (2003) 3276-3284
50. Grossman S.A., O'Neill A., Grunnet M., et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 21 (2003) 1485-1491
51. Brandes A.A., and Fiorentino M.V. The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Invest 14 (1996) 551-559
52. Macdonald D.R., Cascino T.L., Schold Jr. S.C., and Cairncross J.G. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8 (1990) 1277-1280
53. Wong E.T., Hess K.R., Gleason M.J., et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17 (1999) 2572
54. Osoba D., Aaronson N.K., Muller M., et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol 34 (1997) 263-278
55. Baker F., Chang S., Prados M., and Gutin P. Response to carmustine (BCNU), tumor control, and survival in recurrent glioblastoma multiforme (GM). In Proceedings of ASCO (1996)
56. Kappelle A.C., Postma T.J., Taphoorn M.J., et al. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 56 (2001) 118-120
57. Yung W.K., Prados M.D., Yaya-Tur R., et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17 (1999) 2762-2771
58. Brada M., Hoang-Xuan K., Rampling R., et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12 (2001) 259-266
59. Brandes A.A., Ermani M., Basso U., et al. Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. Oncology 63 (2002) 38-41
60. Brandes A.A., Basso U., Reni M., et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol 22 (2004) 1598-1604
61. Groves M.D., Puduvalli V.K., Hess K.R., et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20 (2002) 1383-1388
62. Jaeckle K.A., Hess K.R., Yung W.K., et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 21 (2003) 2305-2311
63. Brandes A.A., Tosoni A., Cavallo G., et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95 (2006) 1155-1160
64. Wick W., Steinbach J.P., Kuker W.M., et al. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 62 (2004) 2113-2115
65. Tosoni A., Cavallo G., Ermani M., et al. Is protracted low-dose temozolomide feasible in glioma patients?. Neurology 66 (2006) 427-429
66. Cokgor I., Friedman H.S., and Friedman A.H. Chemotherapy for adults with malignant glioma. Cancer Invest 17 (1999) 264-272
67. Brandes A.A., Tosoni A., Basso U., et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22 (2004) 4779-4786
68. Franceschi E., Omuro A.M., Lassman A.B., et al. Salvage temozolomide for prior temozolomide responders. Cancer 104 (2005) 2473-2476
69. Rich J.N., Reardon D.A., Peery T., et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22 (2004) 133-142
70. Franceschi E., Cavallo G., Lonardi S., et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer (2007)
71. Van Den Bent M., Brandes A.A., Rampling R., et al. Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034. In Proceedings of ASCO (2007)
72. Vredenburgh J.J., Desjardins A., Herndon II J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25 (2007) 4722-4729
73. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83-95
74. Chang S.M., Wen P., Cloughesy T., et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23 (2005) 357-361
75. Galanis E., Buckner J.C., Maurer M.J., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23 (2005) 5294-5304
76. Corn B.W., Yousem D.M., Scott C.B., et al. White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02). Cancer 74 (1994) 2828-2835
77. Crossen J.R., Garwood D., Glatstein E., and Neuwelt E.A. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12 (1994) 627-642
78. Klein M., Heimans J.J., Aaronson N.K., et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360 (2002) 1361-1368
79. Gregor A., and Cull A. Radiotherapy for malignant glioma. BMJ 313 (1996) 1500-1501
80. Brandes A.A., Pasetto L.M., Lumachi F., and Monfardini S. Endocrine dysfunctions in patients treated for brain tumors: incidence and guidelines for management. J Neurooncol 47 (2000) 85-92
81. Weir B., Band P., Urtasun R., et al. Radiotherapy and CCNU in the treatment of high-grade supratentorial astrocytomas. J Neurosurg 45 (1976) 129-134
82. Walker M.D. The contemporary role of chemotherapy in the treatment of malignant brain tumor. Clin Neurosurg 25 (1978) 388-396
83. Solero C.L., Monfardini S., Brambilla C., et al. Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin Trials 2 (1979) 43-48
84. Walker M.D., Green S.B., Byar D.P., et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303 (1980) 1323-1329
85. Eyre H.J., Quagliana J.M., Eltringham J.R., et al. Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. A Southwest Oncology Group Report. J Neurooncol 1 (1983) 171-177
86. Green S.B., Byar D.P., Walker M.D., et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67 (1983) 121-132
87. Afra D., Kocsis B., Dobay J., and Eckhardt S. Combined radiotherapy and chemotherapy with dibromodulcitol and CCNU in the postoperative treatment of malignant gliomas. J Neurosurg 59 (1983) 106-110
88. Hatlevoll R., Lindegaard K.F., Hagen S., et al. Combined modality treatment of operated astrocytomas grade 3 and 4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy. Stage II of a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 56 (1985) 41-47
89. Nelson D.F., Diener-West M., Weinstein A.S., et al. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. Int J Radiat Oncol Biol Phys 12 (1986) 1793-1800
90. Takakura K., Abe H., Tanaka R., et al. Effects of ACNU and radiotherapy on malignant glioma. J Neurosurg 64 (1986) 53-57
91. Trojanowski T., Peszynski J., Turowski K., et al. Postoperative radiotherapy and radiotherapy combined with CCNU chemotherapy for treatment of brain gliomas. J Neurooncol 6 (1988) 285-291
92. Shapiro W.R., Green S.B., Burger P.C., et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 71 (1989) 1-9
93. Levin V.A., Silver P., Hannigan J., et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18 (1990) 321-324
94. Shapiro W.R., Green S.B., Burger P.C., et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 76 (1992) 772-781
95. Dinapoli R.P., Brown L.D., Arusell R.M., et al. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol 11 (1993) 1316-1321
96. Hildebrand J., Sahmoud T., Mignolet F., et al. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group. Neurology 44 (1994) 1479-1483
97. Elliott T.E., Dinapoli R.P., O'Fallon J.R., et al. Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma. J Neurooncol 33 (1997) 239-250
98. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 19 (2001) 509-518